Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Shares of Esperion Therapeutics (NASDAQ:ESPR) surged more than 10% in extended-hours trading on Monday after the company said that the U.S. Food and Drug Administration (FDA) has removed the peroxisome proliferator-activated receptor (PPAR) partial clinical hold on ETC-1002
The action by the FDA will now allow ESPR to conduct clinical trials exceeding six months in duration and, according to the company, it is an important milestone on the path toward initiation of its Phase 3 clinical program for ETC-1002 later this year
ESPR's ETC-1002 is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with therapies currently available for lowering LDL-cholesterol. ETC-1002 is being developed primarily for patients with hypercholesterolemia and a history of statin intolerance.
- Warning! GuruFocus has detected 2 Warning Signs with ESPR. Click here to check it out.
- ESPR 15-Year Financial Data
- The intrinsic value of ESPR
- Peter Lynch Chart of ESPR
ESPR is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol-lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.
Integrated Device Technology, Inc. (NASDAQ:IDTI)
Integrated Device Technology (NASDAQ:IDTI) reported strong performance on its financial results, driven primarily by strength in its High Performance Computing and Communications businesses.
For its third quarter fiscal 2015, IDTI posted revenue from continuing operations of $151.2 million, an increase of 10.3% sequentially and 21.3% year over year, and non-GAAP net income of $38.7 million or $0.25 per diluted share, compared with non-GAAP net income of $31.8 million or $0.20 per diluted share in the previous quarter, and non-GAAP net income of $25.9 million or $0.17 per diluted share reported in the same period the prior year, these results better than the Capital IQ Consensus Estimate of $0.22 earnings per share on revenues of $142.68 million for the period
IDTI said that with its ongoing focus on operational excellence and its targeted investments in areas that offer the highest potential return, the company is poised to continue leveraging its business and technology strength and anticipates driving sustainable and profitable growth in the future.
IDTI develops system-level solutions that optimize its customers’ applications. IDTI uses its market leadership in timing, serial switching and interfaces, and adds analog and system expertise to provide complete application-optimized, mixed-signal solutions for the communications, computing and consumer segments.
Crown Equity Holdings Inc. (CRWE)
Crown Equity Holdings (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included Concord, California ( www.concord.crwe-pr.com ) into the CRWE Network.
Concord is the largest city in Contra Costa County, California. It is a major regional suburban East Bay center within the San Francisco Bay Area and is 31 miles (50 km) east of San Francisco.
The City of Concord had an estimated population in 2013 (U.S. Census Bureau) of 125,880, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally.
The CRWE Network has reached the 1,487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday.
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer